Ind-Swift Laboratories Limited has completed the allotment of equity shares under its Employee Incentive Scheme 2014, marking another step in its employee benefit initiatives. The pharmaceutical company informed stock exchanges about this corporate action through a regulatory filing dated March 31, 2026.

Share Allotment Details

The Compensation Committee of Ind-Swift Laboratories approved the allotment of 1,25,000 equity shares to eligible employees during its meeting held on March 31, 2026. The allotment was conducted under the Employee Incentive Scheme 2014, which was originally filed with stock exchanges on June 2, 2015.

Updated Share Capital Structure

Following the allotment, the company's share capital structure has been revised. The paid-up equity share capital now stands at ₹86,83,65,580, representing an increase from the previous capital base.

Regulatory Compliance

The allotment was conducted in compliance with SEBI regulations, specifically under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has provided detailed disclosures as required under Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

Key regulatory aspects include:

• The shares are identical in all respects to existing equity shares
• No lock-in period applies to the allotted shares
• The shares are issued in demat form with ISIN number INE915B01019
• No listing fees are payable for this allotment

Stock Exchange Listing

Ind-Swift Laboratories' equity shares are listed on both BSE Limited and National Stock Exchange of India Limited. The company trades under the scrip code 532305 on BSE and symbol INDSWFTLAB on NSE. The newly allotted shares will be traded on both exchanges without any restrictions.

The Employee Incentive Scheme 2014 demonstrates the company's commitment to employee participation in its growth story through equity-based compensation. The scheme allows eligible employees to acquire company shares at predetermined prices, aligning their interests with long-term shareholder value creation.

Ind-Swift Laboratories has completed the dispatch of its comprehensive postal ballot notice for significant leadership restructuring and published mandatory newspaper advertisements in compliance with SEBI regulations. The pharmaceutical company confirmed the completion of all procedural requirements for its four special resolutions involving key management appointments and remuneration changes.

Postal Ballot Notice Dispatch Completion

The company officially completed the dispatch of postal ballot notices and published newspaper advertisements on March 31, 2026, in Financial Express and Jansatta newspapers. This follows the board meeting held on March 27, 2026, where the leadership restructuring initiative was approved.

Leadership Restructuring Initiative

The organizational restructuring aims to strengthen operational focus and enhance decision-making capabilities. N.R. Munjal will transition from Chairman & Managing Director to Chairman & Whole-Time Director, effective February 1, 2026, continuing until March 22, 2028.

E-voting Process and Timeline

Shareholders can participate through remote e-voting facilitated by CDSL during the entire month of April 2026. The company has appointed Sh. Vishal Arora (Membership No. 4566) as Scrutinizer for conducting the postal ballot process transparently.

Remuneration Structure

The proposed remuneration packages reflect competitive compensation aligned with industry standards. Each executive position carries specific salary ranges and comprehensive benefit packages.

Strategic Vision and Governance

The leadership restructuring creates focused operational divisions while maintaining strategic oversight. Himanshu Jain will oversee domestic operations, while Sahil Munjal will manage global operations, enabling specialized expertise in respective business verticals.

The company has also appointed M/s. Jain & Associates, Chartered Accountants, as Internal Auditors for FY 2026-27, demonstrating continued focus on governance and internal controls. This comprehensive transformation positions Ind-Swift Laboratories for its next phase of growth, balancing continuity with change to serve stakeholder interests effectively.